Silje Engdal1, Aslak Steinsbekk, Olbjørn Klepp, Odd Georg Nilsen. 1. Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Medical Technical Research Centre, 3rd Floor West, Olav Kyrresgt. 9, N-7489, Trondheim, Norway. silje.engdal@ntnu.no
Abstract
GOALS OF WORK: This survey aims to explore the differences between cancer patients undergoing chemotherapeutic treatment with palliative or curative intention with respect to concurrent herbal use, experiences of adverse effects, motives of herbal intake, and communication about herbal use with health care providers. MATERIALS AND METHODS: One hundred and twelve adult cancer patients from the west coast of Central Norway, currently undergoing chemotherapeutic treatment, were recruited to a cross-sectional descriptive survey. MAIN RESULTS: Palliative and curative patients used herbal remedies concurrent with chemotherapy equally frequent (37% and 38%). One palliative patient reported adverse effects when doubling the dose of injected mistletoe used. Garlic was only used by palliative patients (p = 0.009) who also tended to have a more frequent everyday herbal use (78% vs 67%, respectively) than curative patients (p = 0.075). Curative patients, however, used herbal remedies more often to counteract adverse reactions (31% vs 3%, respectively; p = 0.026). A bivariate logistic regression, which was adjusted for age, showed that palliative patients used herbal remedies more frequently to improve their immune system (adjusted OR = 7.5, 95% CI = 1.1-49.7). CONCLUSIONS: This is the first survey comparing concurrent herbal use between cancer patients undergoing palliative or curative chemotherapy. Both groups frequently use herbal remedies concurrent with chemotherapy, but with a slightly different intent. The frequent concurrent use emphasizes the need for clinicians to include questions on complementary and alternative medicine in routine history taking and for further studies on possible herb-drug interactions among the cancer patient.
GOALS OF WORK: This survey aims to explore the differences between cancerpatients undergoing chemotherapeutic treatment with palliative or curative intention with respect to concurrent herbal use, experiences of adverse effects, motives of herbal intake, and communication about herbal use with health care providers. MATERIALS AND METHODS: One hundred and twelve adult cancerpatients from the west coast of Central Norway, currently undergoing chemotherapeutic treatment, were recruited to a cross-sectional descriptive survey. MAIN RESULTS: Palliative and curative patients used herbal remedies concurrent with chemotherapy equally frequent (37% and 38%). One palliative patient reported adverse effects when doubling the dose of injected mistletoe used. Garlic was only used by palliative patients (p = 0.009) who also tended to have a more frequent everyday herbal use (78% vs 67%, respectively) than curative patients (p = 0.075). Curative patients, however, used herbal remedies more often to counteract adverse reactions (31% vs 3%, respectively; p = 0.026). A bivariate logistic regression, which was adjusted for age, showed that palliative patients used herbal remedies more frequently to improve their immune system (adjusted OR = 7.5, 95% CI = 1.1-49.7). CONCLUSIONS: This is the first survey comparing concurrent herbal use between cancerpatients undergoing palliative or curative chemotherapy. Both groups frequently use herbal remedies concurrent with chemotherapy, but with a slightly different intent. The frequent concurrent use emphasizes the need for clinicians to include questions on complementary and alternative medicine in routine history taking and for further studies on possible herb-drug interactions among the cancerpatient.
Authors: T Risberg; A Kolstad; Y Bremnes; H Holte; E A Wist; O Mella; O Klepp; T Wilsgaard; B R Cassileth Journal: Eur J Cancer Date: 2004-03 Impact factor: 9.162
Authors: Jennifer S Yates; Karen M Mustian; Gary R Morrow; Leslie J Gillies; Devi Padmanaban; James N Atkins; Brian Issell; Jeffrey J Kirshner; Lauren K Colman Journal: Support Care Cancer Date: 2005-02-15 Impact factor: 3.603
Authors: A Molassiotis; P Fernández-Ortega; D Pud; G Ozden; J A Scott; V Panteli; A Margulies; M Browall; M Magri; S Selvekerova; E Madsen; L Milovics; I Bruyns; G Gudmundsdottir; S Hummerston; A M-A Ahmad; N Platin; N Kearney; E Patiraki Journal: Ann Oncol Date: 2005-02-02 Impact factor: 32.976
Authors: John Baptist Asiimwe; Prakash B Nagendrappa; Esther C Atukunda; Mauda M Kamatenesi; Grace Nambozi; Casim U Tolo; Patrick E Ogwang; Ahmed M Sarki Journal: Evid Based Complement Alternat Med Date: 2021-05-17 Impact factor: 2.650
Authors: Agnete E Kristoffersen; Jorunn V Nilsen; Trine Stub; Johanna Hök Nordberg; Barbara Wider; Dana Mora; Kiwumulo Nakandi; Mona Bjelland Journal: BMC Complement Med Ther Date: 2022-07-29